Oncotype DX not cost-effective for low-risk breast cancer
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk
Read more
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk
Read more(HealthDay)—Many women are not knowledgeable about ovarian cancer before diagnosis despite most women experiencing prediagnosis symptoms, according to a report
Read more